Eating disorders Events Sleep and mental health 
Psychiatric Times
JULY 8, 2025
The safety profile of Caplyta remains consistent, with headache as the most common adverse event. An sNDA for Caplyta as adjunctive therapy in major depressive disorder is under FDA review, showing robust efficacy in phase 3 studies. Caplyta’s safety profile was consistent with the existing body of clinical data.
Psychiatric Times
JULY 1, 2025
SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Healthcare professionals should monitor weight and growth in young patients on these medications and consider alternative treatments if adverse effects occur.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Psychiatric Times
JUNE 13, 2025
of patients who were prescribed antipsychotics for their psychiatric illness and had evidence of tardive dyskinesia (TD) had TD recorded properly in their electronic health records, supporting the idea that TD is often underreported and misdiagnosed and, therefore, not treated appropriately.
Psychiatric Times
JULY 10, 2025
The treatment demonstrated a favorable safety profile, with most adverse events being transient and resolving on the same day. Most of the reported adverse events were transient and occurred on the day that the participant received the dose, and most events resolved that same day.
Psychiatric Times
JUNE 12, 2025
If one wishes to understand an idea such as neuroplasticity, or the logistics of synaptic transmission, or the ramifications of an event like enzyme inhibition or competitive receptor binding, it helps to explain in concrete terms the jobs of key players in a given system. First, let’s differentiate conceptual from sheer factual content.
Lightwork
JUNE 19, 2025
The Impact of Trauma on Women’s Mental Health Women experience and process trauma differently than men, with distinct neurobiological and psychological responses. This is supported by research, which indicates that women’s brains respond differently to traumatic experiences, leading to various long-term health issues.
Psychiatric Times
JULY 7, 2025
McIntyre, MD, FRCPC Key Takeaways Incretin-based treatments, especially GLP-1 RAs, may address comorbidities in mental disorders and have direct CNS effects, potentially modifying disease progression. The GLP-1 RAs as Psychiatric Medications? The GLP-1 RAs as Psychiatric Medications? The GLP-1 RAs as Psychiatric Medications?
Expert insights. Personalized for you.
89 
Let's personalize your content